Crude oil price fluctuations affect upstream and downstream companies differently. Upstream firms benefit from higher prices, ...

bp will restructure into two business segments, Upstream and Downstream, from 1 July 2026, replacing its current ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

BP has set out plans to reorganize its operations into two business segments from July 1, simplifying its organizational ...

In this GEN webinar, our speakers will examine five common planning gaps that can contribute to bottlenecks, including single-source material dependency, raw material pack size selection, sensitive ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

Osmolality is a well-established parameter for upstream bioprocessing, formulation, analytical development and QC applications throughout the manufacturing of biological drugs. A recent publication ...

Biopharmaceutical downstream processing requires precise control of multiple unit operations—from chromatography and filtration to viral inactivation—to ensure product quality and therapeutic efficacy ...

With the recent FDA approval of the CAR T-cell therapies Kymriah ® from Novartis and Yescarta ® from Kite Pharma, there has been a renewed interest in bioprocessing and the manufacturing facilities ...